Integrated Filing — IndAS



General information about company

Scrip Code 524816
NSE Symbol NATCOPHARM
MSEI Symbol NOTLISTED
ISIN INE987B01026
Name of company NATCO PHARMA LIMITED
Type of company Main Board
Class of security Equity
Date of start of financial year 01-04-2026
Date of end of financial year 31-03-2027
Date of board meeting when results were approved 13-11-2026
Date on which prior intimation of the meeting for considering financial results was informed to the exchange 29-10-2026
Description of presentation currency INR
Level of rounding used in financial results Lakhs
Reporting Type Quarterly
Reporting Quarter Second quarter
Nature of report standalone or consolidated Standalone
Whether results are audited or unaudited for the quarter ended Unaudited
Whether results are audited or unaudited for the Year to date for current period ended/year ended Unaudited
Segment Reporting Single segment
Description of single segment Pharmaceuticals
Start date and time of board meeting 13-11-2026   11:50:00
End date and time of board meeting 13-11-2026   14:00:00
Whether cash flow statement is applicable on company Yes
Type of cash flow statement Cash Flow Indirect
Declaration of unmodified opinion or statement on impact of audit qualification Not applicable
Whether the company has any related party? Yes
Whether the company has entered into any Related Party transaction during the selected half year for which it wants to submit disclosure? Yes
(I) We declare that the acceptance of fixed deposits by the bans/Non-Banking Finance Company are at the terms uniformly applicable/offered to all shareholders/public NA
(II) We declare that the scheduled commercial bank, as per RBI circular RBI/DBR/2015-16/19 dated March 03, 2016, has allowed additional interest of one per cent per annum, over and above the rate of interest mentioned in the schedule of interest rates on savings or a term deposits of banks staff and their exclusive associations as well as on deposits of Chairman, Chairman & Managing Director, Executive Director or such other Executives appointed for a fixed tenure. NA
Whether the company is a high value debt listed entity according to regulation 15 (1A)? No
(a) If answer to above question is Yes, whether complying with proviso to regulation 23 (9), i.e., submitting RPT disclosures on the day of results publication?
(b) If answer to above question is No, please explain the reason for not complying.
Whether the updated Related Party Transactions (RPT) Policy (in compliance with Reg. 23 of SEBI LODR) has been uploaded on the website of the Company? Yes
Latest Date on which RPT policy is updated 28-05-2025
Indicate Company website link for updated RPT policy of the Company https://admin.natcopharma.co.in/wp-content/uploads/2025/06/Related-Party-Transaction-Policy.pdf
Whether statement on deviation or variation for proceeds of public issue, rights issue, preferential issue, qualified institutions placement etc. is applicable to the company for the current quarter? No
No. of times funds raised during the quarter
Whether the disclosure for the Default on Loans and Debt Securities is applicable to the entity? No
The said disclsoure is not applicable to the Company



Financial Results Ind-AS

Amount in (Lakhs)

Particulars 3 months/ 6 months ended (dd-mm-yyyy) Year to date figures for current period ended (dd-mm-yyyy)
A Date of start of reporting period 01-07-2026 01-04-2026
B Date of end of reporting period 30-09-2026 30-09-2026
C Whether results are audited or unaudited Unaudited Unaudited
D Nature of report standalone or consolidated Standalone Standalone
1 Income
Revenue from operations 85,450.00 1,45,110.00
Other income 4,030.00 8,860.00
Total income 89,480.00 1,53,970.00
2 Expenses
(a) Cost of materials consumed 17,170.00 32,950.00
(b) Purchases of stock-in-trade 4,680.00 4,720.00
(c) Changes in inventories of finished goods, work-in-progress and stock-in-trade (3,380.00) (3,530.00)
(d) Employee benefit expense 17,500.00 32,640.00
(e) Finance costs 1,560.00 2,520.00
(f) Depreciation, depletion and amortisation expense 4,400.00 8,670.00
(f) Other Expenses
1 Other Expenses 27,850.00 46,100.00
Total other expenses 27,850.00 46,100.00
Total expenses 69,780.00 1,24,070.00
3 Total profit before exceptional items and tax 19,700.00 29,900.00
4 Exceptional items 0.00 0.00
5 Total profit before tax 19,700.00 29,900.00
6 Tax expense
7 Current tax 2,240.00 3,340.00
8 Deferred tax 3,140.00 4,780.00
9 Total tax expenses 5,380.00 8,120.00
10 Net movement in regulatory deferral account balances related to profit or loss and the related deferred tax movement 0.00 0.00
11 Net Profit Loss for the period from continuing operations 14,320.00 21,780.00
12 Profit (loss) from discontinued operations before tax 0.00 0.00
13 Tax expense of discontinued operations 0.00 0.00
14 Net profit (loss) from discontinued operation after tax 0.00 0.00
15 Share of profit (loss) of associates and joint ventures accounted for using equity method 0.00 0.00
16 Total profit (loss) for period 14,320.00 21,780.00
17 Other comprehensive income net of taxes 110.00 1,180.00
18 Total Comprehensive Income for the period 14,430.00 22,960.00
19 Total profit or loss, attributable to
Profit or loss, attributable to owners of parent
Total profit or loss, attributable to non-controlling interests
20 Total Comprehensive income for the period attributable to
Comprehensive income for the period attributable to owners of parent
Total comprehensive income for the period attributable to owners of parent non-controlling interests
21 Details of equity share capital
Paid-up equity share capital 3,580.00 3,580.00
Face value of equity share capital 2 2
27 Details of debt securities
22 Reserves excluding revaluation reserve
23 Earnings per share
i Earnings per equity share for continuing operations
Basic earnings (loss) per share from continuing operations 8 12.16
Diluted earnings (loss) per share from continuing operations 8 12.16
ii Earnings per equity share for discontinued operations
Basic earnings (loss) per share from discontinued operations 0 0
Diluted earnings (loss) per share from discontinued operations 0 0
ii Earnings per equity share
Basic earnings (loss) per share from continuing and discontinued operations 8 12.16
Diluted earnings (loss) per share from continuing and discontinued operations 8 12.16
24 Debt equity ratio
25 Debt service coverage ratio
26 Interest service coverage ratio
27 Disclosure of notes on financial results



Remarks

Debt equity ratio
Debt service coverage ratio
Interest service coverage ratio


Statement of Asset and Liabilities

Amount in (Lakhs)

Particulars Year ended (dd-mm-yyyy)
Date of start of reporting period 01-04-2026
Date of end of reporting period 30-09-2026
Whether results are audited or unaudited Unaudited
Nature of report standalone or consolidated Standalone
Assets
1 Non-current assets
Property, plant and equipment 2,57,020.00
Capital work-in-progress 37,580.00
Investment property
Goodwill 0.00
Other intangible assets 9,070.00
Intangible assets under development
Biological assets other than bearer plants
Investments accounted for using equity method
Non-current financial assets
Non-current investments 9,730.00
Trade receivables, non-current
Loans, non-current 260.00
Other non-current financial assets
1 Other financial assests 3,000.00
Total of other non-current financial assets 3,000.00
Total non-current financial assets 12,990.00
Deferred tax assets (net) 17,850.00
Other non-current assets
1 Non-current tax assests (Net) 1,080.00
2 Investment in Subsidiaries 3,62,720.00
3 Other non-current assets 11,500.00
Total of other non-current assets 3,75,300.00
Total non-current assets 7,09,810.00
2 Current assets
Inventories 74,450.00
Current financial asset
Current investments 44,840.00
Trade receivables, current 69,930.00
Cash and cash equivalents 3,300.00
Bank balance other than cash and cash equivalents 76,440.00
Loans, current 1,060.00
Other current financial assets
Total of other current financial assets 44,510.00
Total current financial assets 2,40,080.00
Current tax assets (net)
Other current assets
1 Other current assets 35,650.00
Total of other current assets 35,650.00
Total current assets 3,50,180.00
3 Non-current assets classified as held for sale
4 Regulatory deferral account debit balances and related deferred tax Assets
Total assets 10,59,990.00
Equity and liabilities
1 Equity
Equity attributable to owners of parent
Equity share capital 3,580.00
Other equity 8,71,950.00
Total equity attributable to owners of parent 8,75,530.00
Non controlling interest
Total equity 8,75,530.00
2 Liabilities
Non-current liabilities
Non-current financial liabilities
Borrowings, non-current 0.00
Trade payables, non-current
(A) Total outstanding dues of micro enterprises and small enterprises
(B) Total outstanding dues of creditors other than micro enterprises and small enterprises
Total Trade payable
Other non-current financial liabilities
1 Lease liabilities 40.00
2 Other financial liabilities 580.00
Total of other non-current financial liabilities 620.00
Total non-current financial liabilities 620.00
Provisions, non-current 7,480.00
Deferred tax liabilities (net)
Deferred government grants, Non-current
Other non-current liabilities
Total of other non-current liabilities
Total non-current liabilities 8,100.00
Current liabilities
Current financial liabilities
Borrowings, current 1,02,670.00
Trade payables, current
(A) Total outstanding dues of micro enterprises and small enterprises 2,440.00
(B) Total outstanding dues of creditors other than micro enterprises and small enterprises 32,160.00
Total Trade payable 34,600.00
Other current financial liabilities
1 Lease liabilities 180.00
2 Other current financial liabilities 13,610.00
Total of other current financial liabilities 13,790.00
Total current financial liabilities 1,51,060.00
Other current liabilities 13,580.00
1 Other current liabilities 13,580.00
Total of other current liabilities 13,580.00
Provisions, current 11,720.00
Current tax liabilities (Net)
Deferred government grants, Current
Total current liabilities 1,76,360.00
3 Liabilities directly associated with assets in disposal group classified as held for sale
4 Regulatory deferral account credit balances and related deferred tax liability
Total liabilities 1,84,460.00
Total equity and liabilites 10,59,990.00
Disclosure of notes on assets and liabilities



Format for Reporting Segment wise Revenue, Results and Capital Employed along with the company results

Amount in (Lakhs)

Particulars 3 months/ 6 month ended (dd-mm-yyyy) Year to date figures for current period ended (dd-mm-yyyy)
Date of start of reporting period 01-07-2026 01-04-2026
Date of end of reporting period 30-09-2026 30-09-2026
Whether results are audited or unaudited Unaudited Unaudited
Nature of report standalone or consolidated Standalone Standalone
1 Segment Revenue (Income)
(net sale/income from each segment should be disclosed)
Total Segment Revenue
Less: Inter segment revenue
Revenue from operations
2 Segment Result
Profit (+) / Loss (-) before tax and interest from each segment
Total Profit before tax
i. Finance cost
ii. Other Unallocable Expenditure net off Unallocable income
Profit before tax
3 (Segment Asset - Segment Liabilities)
Segment Asset
Total Segment Asset
Un-allocable Assets null null
Net Segment Asset null null
4 Segment Liabilities
Segment Liabilities
Total Segment Liabilities
Un-allocable Liabilities null null
Net Segment Liabilities null null
Disclosure of notes on segments



Other Comprehensive Income

Amount in (Lakhs)

Particulars 3 months/ 6 months ended (dd-mm-yyyy) Year to date figures for current period ended (dd-mm-yyyy)
A Date of start of reporting period 01-07-2026 01-04-2026
B Date of end of reporting period 30-09-2026 30-09-2026
C Whether results are audited or unaudited Unaudited Unaudited
D Nature of report standalone or consolidated Standalone Standalone
Other comprehensive income [Abstract]
1 Amount of items that will not be reclassified to profit and loss
1 Fair value changes in Equity investments through OCI 130.00 1,380.00
2 Tax impact on fair value changes in equity investments through OCI (20.00) (200.00)
Total Amount of items that will not be reclassified to profit and loss 110.00 1,180.00
2 Income tax relating to items that will not be reclassified to profit or loss 0.00 0.00
3 Amount of items that will be reclassified to profit and loss
Total Amount of items that will be reclassified to profit and loss
4 Income tax relating to items that will be reclassified to profit or loss 0.00 0.00
5 Total Other comprehensive income 110.00 1,180.00



Cash flow statement, indirect

Amount in (Lakhs)

Particulars Year ended (dd-mm-yyyy)
A Date of start of reporting period 01-04-2026
B Date of end of reporting period 30-09-2026
C Whether results are audited or unaudited Unaudited
D Nature of report standalone or consolidated Standalone
Statement of cash flows
Cash flows from used in operating activities
Profit before tax 29,900.00
Adjustments for reconcile profit (loss)
Adjustments for finance costs 2,520.00
Adjustments for decrease (increase) in inventories (2,090.00)
Adjustments for decrease (increase) in trade receivables, current 6,100.00
Adjustments for decrease (increase) in trade receivables, non-current 0.00
Adjustments for decrease (increase) in other current assets 0.00
Adjustments for decrease (increase) in other non-current assets (2,570.00)
Adjustments for other financial assets, non-current 0.00
Adjustments for other financial assets, current (10.00)
Adjustments for other bank balances 0.00
Adjustments for increase (decrease) in trade payables, current (1,930.00)
Adjustments for increase (decrease) in trade payables, non-current 0.00
Adjustments for increase (decrease) in other current liabilities 0.00
Adjustments for increase (decrease) in other non-current liabilities 0.00
Adjustments for depreciation and amortisation expense 8,670.00
Adjustments for impairment loss reversal of impairment loss recognised in profit or loss 0.00
Adjustments for provisions, current (21,990.00)
Adjustments for provisions, non-current 0.00
Adjustments for other financial liabilities, current 2,590.00
Adjustments for other financial liabilities, non-current 2,290.00
Adjustments for unrealised foreign exchange losses gains (410.00)
Adjustments for dividend income 30.00
Adjustments for interest income 7,480.00
Adjustments for share-based payments 0.00
Adjustments for fair value losses (gains) 0.00
Adjustments for undistributed profits of associates 0.00
Other adjustments for which cash effects are investing or financing cash flow 0.00
Other adjustments to reconcile profit (loss) 220.00
Other adjustments for non-cash items 500.00
Share of profit and loss from partnership firm or association of persons or limited liability partnerships 0.00
Total adjustments for reconcile profit (loss) (13,620.00)
Net cash flows from (used in) operations 16,280.00
Dividends received 0.00
Interest paid 0.00
Interest received 0.00
Income taxes paid (refund) 3,730.00
Other inflows (outflows) of cash 0.00
Net cash flows from (used in) operating activities 12,550.00
Cash flows from used in investing activities
Cash flows from losing control of subsidiaries or other businesses 0.00
Cash flows used in obtaining control of subsidiaries or other businesses 1,03,410.00
Other cash receipts from sales of equity or debt instruments of other entities 0.00
Other cash payments to acquire equity or debt instruments of other entities 0.00
Other cash receipts from sales of interests in joint ventures 0.00
Other cash payments to acquire interests in joint ventures 0.00
Cash receipts from share of profits of partnership firm or association of persons or limited liability partnerships 0.00
Cash payment for investment in partnership firm or association of persons or limited liability partnerships 0.00
Proceeds from sales of property, plant and equipment 80.00
Purchase of property, plant and equipment 27,960.00
Proceeds from sales of investment property 18,360.00
Purchase of investment property 4,890.00
Proceeds from sales of intangible assets 0.00
Purchase of intangible assets 250.00
Proceeds from sales of intangible assets under development 0.00
Purchase of intangible assets under development 0.00
Proceeds from sales of goodwill 0.00
Purchase of goodwill 0.00
Proceeds from biological assets other than bearer plants 0.00
Purchase of biological assets other than bearer plants 0.00
Proceeds from government grants 0.00
Proceeds from sales of other long-term assets 0.00
Purchase of other long-term assets 0.00
Cash advances and loans made to other parties 230.00
Cash receipts from repayment of advances and loans made to other parties 0.00
Cash payments for future contracts, forward contracts, option contracts and swap contracts 0.00
Cash receipts from future contracts, forward contracts, option contracts and swap contracts 0.00
Dividends received 30.00
Interest received 8,180.00
Income taxes paid (refund) 0.00
Other inflows (outflows) of cash 73,000.00
Net cash flows from (used in) investing activities (37,090.00)
Cash flows from used in financing activities
Proceeds from changes in ownership interests in subsidiaries 0.00
Payments from changes in ownership interests in subsidiaries 0.00
Proceeds from issuing shares 0.00
Proceeds from issuing other equity instruments 0.00
Payments to acquire or redeem entity's shares 0.00
Payments of other equity instruments 0.00
Proceeds from exercise of stock options 0.00
Proceeds from issuing debentures notes bonds etc 0.00
Proceeds from borrowings 56,000.00
Repayments of borrowings 24,280.00
Payments of lease liabilities 100.00
Dividends paid 2,710.00
Interest paid 2,220.00
Income taxes paid (refund) 0.00
Other inflows (outflows) of cash 0.00
Net cash flows from (used in) financing activities 26,690.00
Net increase (decrease) in cash and cash equivalents before effect of exchange rate changes 2,150.00
Effect of exchange rate changes on cash and cash equivalents
Effect of exchange rate changes on cash and cash equivalents 0.00
Net increase (decrease) in cash and cash equivalents 2,150.00
Cash and cash equivalents cash flow statement at beginning of period 1,150.00
Cash and cash equivalents cash flow statement at end of period 3,300.00





Amount in (Lakhs)

Format for Disclosure of Related Party Transactions (applicable only for half-yearly filings i.e., 2nd and 4th quarter)

Sr No. Additional disclosure of related party transactions - applicable only in case the related party transaction relates to loans, inter-corporate deposits, advances or investments made or given by the listed entity/subsidiary. These details need to be disclosed only once, during the reporting period when such transaction was undertaken.
Details of the party (listed entity/subsidiary) entering into the transaction Details of the counterparty Type of related party transaction Details of other related party transaction Value of the related party transaction as approved by the audit committee Remarks on approval by audit committee Value of the related party transaction ratified by the audit committee Date of Audit Committee Meeting where the ratification was approved Value of transaction during the reporting period In case monies are due to either party as a result of the transaction In case any financial indebtedness is incurred to make or give loans, inter-corporate deposits, advances or investments Details of the loans, inter-corporate deposits, advances or investments Notes
Name PAN Name PAN Relationship of the counterparty with the listed entity or its subsidiary Opening balance Closing balance Nature of indebtedness (loan/ issuance of debt/ any other etc.) Details of other indebtedness Cost Tenure Nature (loan/ advance/ intercorporate deposit/ investment ) Interest Rate (%) Tenure Secured/ unsecured Purpose for which the funds will be utilised by the ultimate recipient of funds (endusage)
1 NATCO PHARMA LIMITED Natco Pharma (Canada) Inc. Canada Wholly Owned Subsidiary Sale of goods or services 1,773.70 As per the Companies Act, 2013 1,773.70 1,192.20 (772.40)
2 NATCO PHARMA LIMITED Natco Pharma Asia Pte Ltd, Singapore Wholly Owned Subsidiary Sale of goods or services 775.00 As per the Companies Act, 2013 775.00 168.00 635.50
3 NATCO PHARMA LIMITED Natcofarma Do Brasil Ltda., Brazil Wholly Owned step down Subsidiary Sale of goods or services 15,822.40 As per the Companies Act, 2013 15,822.40 10,014.10 11,807.00
4 NATCO PHARMA LIMITED NATCO Pharma USA LLC, United States of America Wholly Owned step down Subsidiary Sale of goods or services 736.50 As per the Companies Act, 2013 736.50 182.10 676.00
5 NATCO PHARMA LIMITED Natco Lifesciences Philippines Inc., Philippines Wholly Owned Subsidiary Sale of goods or services 188.70 As per the Companies Act, 2013 188.70 318.90 191.30
6 NATCO PHARMA LIMITED Natco Lifesciences Philippines Inc., Philippines Wholly Owned Subsidiary Interest received 6.40 As per the Companies Act, 2013 6.40 1.50 3.40
7 NATCO PHARMA LIMITED Natco Lifesciences Philippines Inc., Philippines Wholly Owned Subsidiary Loan 141.40 As per the Companies Act, 2013 141.40 113.60 259.20
8 NATCO PHARMA LIMITED PT NATCO Lotus Farma Wholly Owned Subsidiary Sale of goods or services 781.20 As per the Companies Act, 2013 781.20 151.10 796.80
9 NATCO PHARMA LIMITED Natco Pharma Colombia SAS Wholly Owned Subsidiary Investment 95.00 As per the Companies Act, 2013 95.00 0.00 0.00
10 NATCO PHARMA LIMITED Natco Pharma South Africa Proprietary Limited Wholly Owned Subsidiary Investment 1,03,319.30 As per the Companies Act, 2013 1,03,319.30 0.00 0.00
11 NATCO PHARMA LIMITED Adcock Ingram Holdings PTY Ltd & Group Associate Company Purchase of goods or services 15.10 As per the Companies Act, 2013 15.10 29.70 0.00
12 NATCO PHARMA LIMITED Adcock Ingram Holdings PTY Ltd & Group Associate Company Any other transaction Reimbursement 672.10 As per the Companies Act, 2013 672.10 0.00 0.00
13 NATCO PHARMA LIMITED Adcock Ingram Holdings PTY Ltd & Group Associate Company Dividend received 18.80 As per the Companies Act, 2013 18.80 0.00 0.00
14 NATCO PHARMA LIMITED Natco Crop Health Sciences Limited Wholly Owned Subsidiary Any other transaction Rental Income 0.20 As per the Companies Act, 2013 0.20 0.10 0.00
15 NATCO PHARMA LIMITED Time Cap Pharma Labs Private Limited Entities�in which Directors have control or have significant�influence Any other transaction Rental Expense 39.80 As per the Companies Act, 2013 39.80 7.20 7.20
16 NATCO PHARMA LIMITED Natco Trust Entities�in which Directors have control or have significant�influence Any other transaction Donations & Contribution to CSR Activities 1,110.80 As per the Companies Act, 2013 1,110.80 0.00 0.00
17 NATCO PHARMA LIMITED Natco Trust Entities�in which Directors have control or have significant�influence Any other transaction Rental Income 0.40 As per the Companies Act, 2013 0.40 0.00 0.00
18 NATCO PHARMA LIMITED V C Nannapaneni Key Managerial Personnel Remuneration 97.50 As per the Companies Act, 2013 97.50 4.80 7.90
19 NATCO PHARMA LIMITED V C Nannapaneni Key Managerial Personnel Any other transaction Rental Expense 18.00 As per the Companies Act, 2013 18.00 3.20 3.20
20 NATCO PHARMA LIMITED Rajeev Nannapaneni Key Managerial Personnel Remuneration 90.00 As per the Companies Act, 2013 90.00 4.90 7.60
21 NATCO PHARMA LIMITED Rajeev Nannapaneni Key Managerial Personnel Any other transaction Rental Expense 18.00 As per the Companies Act, 2013 18.00 3.20 3.20
22 NATCO PHARMA LIMITED Potluri Prasad Sivaramakrishna Key Managerial Personnel Remuneration 84.70 As per the Companies Act, 2013 84.70 6.00 8.00
23 NATCO PHARMA LIMITED Potluri Prasad Sivaramakrishna Key Managerial Personnel Any other transaction Incentive 100.00 As per the Companies Act, 2013 100.00 0.00 0.00
24 NATCO PHARMA LIMITED Dr.Lingarao Donthineni Key Managerial Personnel Remuneration 84.70 As per the Companies Act, 2013 84.70 6.10 8.00
25 NATCO PHARMA LIMITED Dr.Lingarao Donthineni Key Managerial Personnel Any other transaction Incentive 180.00 As per the Companies Act, 2013 180.00 0.00 0.00
26 NATCO PHARMA LIMITED Amit Parekh Chief Financial Officer Remuneration 90.90 As per the Companies Act, 2013 90.90 7.60 15.00
27 NATCO PHARMA LIMITED Venkat Ramesh Chekuri Company Secretary & Compliance Officer Remuneration 15.10 As per the Companies Act, 2013 15.10 1.30 1.80
28 NATCO PHARMA LIMITED Agnihotra Dakshina Murty Chavali Independent Director Any other transaction Sitting fee 8.00 As per the Companies Act, 2013 8.00 0.00 0.00
29 NATCO PHARMA LIMITED Dronadula Vijaya Bhaskar Independent Director Any other transaction Sitting fee 9.50 As per the Companies Act, 2013 9.50 0.00 0.00
30 NATCO PHARMA LIMITED Lakshminarayana Bolisetty Independent Director Any other transaction Sitting fee 8.00 As per the Companies Act, 2013 8.00 0.00 0.00
31 NATCO PHARMA LIMITED Suma Kantipudi Independent Director Any other transaction Sitting fee 5.00 As per the Companies Act, 2013 5.00 0.00 0.00
32 NATCO PHARMA LIMITED Nitin Jain Independent Director Any other transaction Sitting fee 7.50 As per the Companies Act, 2013 7.50 0.00 0.00
Total value of transaction during the reporting period 1,26,313.70